Literature DB >> 16778308

Immune responses in kala-azar.

Samiran Saha1, Smriti Mondal, Antara Banerjee, Jayeeta Ghose, Sudipta Bhowmick, Nahid Ali.   

Abstract

Human infection with Leishmania results in diverse clinical and immunopathological situations. The capacity of the parasites to cause this wide range of disease manifestations depends upon their ability to evade the immune defense mechanisms by performing a well-tuned orchestra of hostparasite interactions inside the macrophages. While updated knowledge focus on the key role of cell-mediated immunity (CMI) in protection, the survival strategies of the parasites leads to the suppression of CMI which can further be aggravated by the co-infections with HIV, tuberculosis etc. The present review describes the immune mechanisms in human leishmaniasis with a special attention to visceral leishmaniasis or kala-azar, one of the most important epidemiological health problems in Indian subcontinent. Modulations of the both humoral and cell-mediated immune responses during asymptomatic infections, active disease and after successful chemotherapy are discussed. The components responsible for the regulation of the critical balance of Th1/Th2 type of responses are re-evaluated. Co-infection of HIV and visceral leishmaniasis and their interdependence has been addressed. Although the specific role of an elevated humoral response in kala-azar is yet to be established, attempts for its application in diagnosis, precisely for the development of field diagnostic techniques, are presented. Also discussed are attempts to utilize the immunogenic potentials of different leishmanial antigens in the development of anti-leishmanial vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778308

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  35 in total

1.  9-O-acetylated sialoglycoproteins are important immunomodulators in Indian visceral leishmaniasis.

Authors:  Angana Ghoshal; Sumi Mukhopadhyay; Bibhuti Saha; Chitra Mandal
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

2.  Atypical lesions as a sign of cutaneous dissemination of visceral leishmaniasis in a human immunodeficiency virus-positive patient simultaneously infected by two viscerotropic Leishmania species.

Authors:  Joanna R Santos-Oliveira; Alda M Da-Cruz; Lucy H S Pires; Elisa Cupolillo; Katrin Kuhls; Carmem B W Giacoia-Gripp; Manoel P Oliveira-Neto
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  Leishmania donovani-specific 25- and 28-kDa urinary proteins activate macrophage effector functions, lymphocyte proliferation and Th1 cytokines production.

Authors:  Vinod Kumar; Jalaj K Gour; Nisha Singh; Surabhi Bajpai; Rakesh K Singh
Journal:  Parasitol Res       Date:  2013-01-19       Impact factor: 2.289

4.  Immune responses of Iranian patients with visceral leishmaniasis and recovered individuals to LCR1 of Leishmania infantum.

Authors:  Hamid M Niknam; Firoozeh Abrishami; Mohammad Doroudian; Mosayeb Rostamian; Maryam Moradi; Vahid Khaze; Davood Iravani
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

5.  Toll-like receptor 4 (TLR4) polymorphisms in Iranian patients with visceral leishmaniasis.

Authors:  Manoochehr Rasouli; Maryam Keshavarz; Mehdi Kalani; Ali Moravej; Simin Kiany; Parisa Badiee
Journal:  Mol Biol Rep       Date:  2012-10-06       Impact factor: 2.316

6.  Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.

Authors:  Abdolvahab Alborzi; Gholamreza Pouladfar; Armin Attar; Fatemeh Falahi; Zahra Jafarpour; Abdollah Karimi; Mohammad Rahim Kadivar
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

7.  Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.

Authors:  Katharina Kronenberg; Sven Brosch; Florian Butsch; Yayoi Tada; Naotaka Shibagaki; Mark C Udey; Esther von Stebut
Journal:  J Invest Dermatol       Date:  2010-06-24       Impact factor: 8.551

8.  Leishmania major abrogates gamma interferon-induced gene expression in human macrophages from a global perspective.

Authors:  Nisha Dogra; Corinna Warburton; W Robert McMaster
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.